SHANGHAI, China, March 12, 2021 -- Genor Biopharma (Stock code: 6998.HK) announced today IND application of GB492 (IMSA101, Stimulator of interferon genes，STING) is under review by NMPA. The Phase I/IIa clinical trials will evaluate the safety and efficacy of GB492 as monotherapy and in combination with recombinant anti-human PD-1/L1 functional monoclonal antibody, in patients with advanced treatment-refractory malignancies.
About GB492 (IMSA101)
GB492 (IMSA101, Stimulator of interferon genes, STING) is the major mediator of innate immune sensing of cancerous cells, licensed from Immunesensor Therapeutic in June 2020. STING agonist, as an immune stimulatory therapy, may further increase the response of immune checkpoint inhibitors for patients. Multiple studies have shown that STING agonists can activate the cGAS-STING signaling and significantly enhance the efficacy of cancer immunity cycle when using in combo with other immune checkpoint inhibitors (ICI), a potential first-in-class therapy.
